

A Systematic Review on the Effects of L-Arginine on Cardiovascular Health

Mrinal Ghosh¹, Shreyasi Das^{2*}

¹B.Sc. Student, Department of Food and Nutrition, Swami Vivekananda University, Barrackpore, Telinipara, Barasat-Barrackpore Road, Bara Kanthalia, West Bengal-700121

²Assistant Professor, Department of Food and Nutrition, Swami Vivekananda University, Barrackpore, Telinipara, Barasat-Barrackpore Road, Bara Kanthalia, West Bengal-700121

*Corresponding e-mail :shreyasi.das7890@gmail.com

Abstract:

L-Arginine is a basic endogenous amino acid and the only substrate of Nitric Oxide Synthase (NOS), responsible for producing Nitric Oxide (NO), a messenger molecule that has numerous effects on cardiovascular system (blood vessels and heart). Nitric Oxide is a Vasodilator which has been seen to reduce Hypertension, Atherosclerosis and other Cardiovascular diseases. Some clinical studies involving healthy volunteers or patients suffering from hypertension and diabetes indicate that it may also regulate vascular homeostasis. Data collected from recent studies suggest that L-arginine could be one of the possible therapeutic molecules to treat different cardiovascular disorders. The majority of L-arginine's documented cardiovascular effects are mediated by nitric oxide synthase's conversion of L-arginine to nitric oxide. L-arginine supplements have demonstrated efficacy in treating the clinical manifestations of a number of disorders linked to vascular dysfunction.

Key Words: L-Arginine, Nitric Oxide, Epithelium, Vasodilation, Hypertension, Atherosclerosis, ADMA(Aseptic Dimethyl arginine)

Introduction :

L-Arginine is a semi-essential amino acid pivotal for vascular function due to its role as the sole precursor of nitric oxide (NO), a key molecule produced by endothelial cells to regulate vasodilation and vascular tone (Wu & Morris, 1998; Gornik& Creager, 2004). A deficiency in L-arginine or an increase in endogenous inhibitors such as asymmetric dimethylarginine (ADMA) may result in reduced NO synthesis, leading to endothelial dysfunction—a hallmark of many cardiovascular diseases (Loscalzo, 2000).

L-arginine, a conditionally essential amino acid, plays a crucial role in maintaining vascular health. A deficiency in L-arginine has been linked to various inflammatory and oxidative processes in the vascular endothelium, potentially contributing to the development of atherosclerosis (Cylwik et al., 2005; Sudar-Milovanovic et al., 2016). The vascular system's normal function relies on nitric oxide (NO) production by vascular endothelial cells. However, oxidative vascular injury, often associated with conditions like obesity or hypertension, can lead to an accumulation of asymmetric dimethyl arginine (ADMA). This, in turn, inhibits NO synthase (NOS), reducing NO production and potentially causing vascular endothelial injury and inflammation (Loscalzo, 2000; Gornik& Creager, 2004).

The Importance of dietary L-arginine intake cannot be overstated, particularly in the context of inflammation and oxidative stress. Recent studies have shown that lower intake of dietary L-arginine is associated with higher levels of C-reactive protein, an inflammatory biomarker (Dana et al., 2008). Furthermore, supplemental L-arginine may help prevent harmful oxidation and reverse endothelial dysfunction, as well as address endothelial dysfunction associated with hypercholesterolemia, smoking, and hypertension (Cylwik et al., 2005; Sudar-Milovanovic et al., 2016). Interestingly, some of L-arginine's antioxidant and anti-inflammatory effects appear to be independent of NO production (Grisham et al., 1999).


This review aims to provide an overview of the current evidence on the role of L-arginine in maintaining cardiovascular health, with a focus on its anti-inflammatory and anti-atherosclerotic properties. We will examine the molecular mechanisms underlying L-arginine's cardiovascular benefits, as well as the clinical evidence supporting its use as a nutritional intervention for promoting cardiovascular health.

Physiological Role of L-Arginine in Humans:

L-Arginine (2-amino-5-guanidinovaleric acid) is the precursor of nitric oxide, an endogenous messenger molecule involved in a variety of endothelium-mediated physiological effects in the vascular system. Acute and chronic administration of L-arginine has been shown to improve endothelial function in animal models of hypercholesterolemia and atherosclerosis (Cylwik et al., 2005; Sudar-Milovanovic et al., 2016). L-Arginine also improves endothelium-dependent vasodilation in humans with hypercholesterolemia and atherosclerosis (Rodrigues-Krause et al., 2019).

Metabolism of L -Arginine :

L-arginine is broken down by several enzymes, including those that produce nitric oxide, a crucial molecule for blood vessel health (Radomski et al., 1990; Wu & Morris, 1998). Our bodies also make L-arginine from another amino acid called citrulline, mainly in the kidneys (Wu & Morris, 1998). When L-arginine is metabolized, it creates important molecules like nitric oxide, creatine, and urea (Wu & Morris, 1998). However, an imbalance in L-arginine metabolism can lead to various health issues, such as high blood pressure, diabetes, and heart disease (Gokce, 2004; Loscalzo, 2000). This imbalance can also affect exercise performance and overall physical health (Park et al., 2023). Maintaining a healthy balance of L-arginine metabolism is essential for supporting cardiovascular health and preventing related diseases (Cylwik et al., 2005; Gornik & Creager, 2004). Additionally, research has shown that supplementing with L-arginine can help restore balance and promote overall well-being (Rodrigues-Krause et al., 2019; Sudar-Milovanovic et al., 2016).



(L-Arginine Pathway)

Beneficiary Effects of L-Arginine on Cardiovascular Health:

Having proper amount of L-arginine is crucial, as there seems to be a connection between L- arginine and heart health. Studies have shown that it acts as a vasodilator, which means it helps to dilate or open up blood vessels. Consequently, it has the potential to improve a number of cardiovascular conditions.

Effect of L-Arginine on Endothelial Function in Humans

Research on the impact of L-arginine on endothelial function in humans has yielded mixed results, which may be attributed to variations in dosage (Bode-Boger et al., 1998). High doses of L-arginine, administered intravenously or intra-arterially, have been shown to cause vasodilation in young, healthy individuals (Radomski et al., 1990). However, endothelium-dependent vasodilation declines with age. Studies have demonstrated that oral L-arginine supplementation can improve endothelial function in individuals with hypercholesterolemia, coronary artery disease, and other conditions (Gornik& Creager, 2004; Rodrigues-Krause et al., 2019). For instance, a study found that intravenous L-arginine infusion improved forearm blood flow response

to methacholine in hypercholesterolemic patients (Gornik& Creager, 2004). Another study showed that oral L-arginine supplementation improved flow-mediated vasodilation of the brachial artery in hypercholesterolemic patients (Gokce, 2004). Additionally, research has explored the effects of L-arginine on endothelial function in patients with coronary artery disease (Loscalzo, 2000). One study found that intracoronary L-arginine infusion improved the coronary blood flow response to acetylcholine in hypercholesterolemic patients (Loscalzo, 2000). Another study demonstrated that long-term administration of L-arginine improved the coronary vasodilator response to acetylcholine and reduced anginal symptoms in patients with angina pectoris (Sudar-Milovanovic et al., 2016). L-arginine has also been studied in other disease states, including essential hypertension, peripheral arterial disease, and congestive heart failure (Cylwik et al., 2005). While some studies have reported improvements in endothelial function, others have found inconsistent results (Dana et al., 2008). Overall, the available evidence suggests that L-arginine supplementation may have beneficial effects on endothelial function in certain populations, particularly those with hypercholesterolemia and coronary artery disease (Rodrigues-Krause et al., 2019). However, further research is needed to fully understand the effects of L-arginine on endothelial function in humans (Park et al., 2023).

Effect of L-Arginine on Blood Platelets

L-arginine has been shown to inhibit platelet aggregation by increasing the production of nitric oxide (NO), which in turn elevates cyclic GMP levels and down-regulates platelet reactivity (Radomski et al., 1990). Studies have demonstrated that L-arginine inhibits platelet aggregation induced by various agents, including collagen, ADP, thrombin, and arachidonic acid (Radomski et al., 1990). The inhibition of platelet aggregation by L-arginine is enantiomer-specific, NADPH-dependent, and Ca^{2+} -dependent, indicating that it is mediated by the NO synthase enzyme (Wu & Morris, 1998). Additionally, L-arginine has been shown to synergize with prostacyclin to inhibit platelet aggregation, and its effects are

potentiated by inhibitors of cyclic GMP phosphodiesterase (Bode-Boger et al., 1998). Overall, the results suggest that L-arginine may have anti-thrombotic effects by inhibiting platelet aggregation, and that dietary supplementation with L-arginine may be a useful strategy for preventing or treating diseases related to platelet dysfunction (Gornik& Creager, 2004; Loscalzo, 2000).

HyperCholesterolemia

L-arginine has been shown to improve endothelial function and reverse endothelial dysfunction in hypercholesterolemic rabbits (Loscalzo, 2000; Gornik& Creager, 2004). Studies using animal models have demonstrated the efficacy of L-arginine supplementation in improving endothelium-dependent vasodilation through both acute intravenous infusion and prolonged oral administration (Wu & Morris, 1998; Cylwik et al., 2005). In vivo experiments have also shown that acute infusion of L-arginine improves endothelium-dependent vasodilation in response to acetylcholine, without affecting endothelium-independent vasodilation (Radomski et al., 1990). Overall, these findings suggest that L-arginine may be a useful adjunctive therapy for the treatment of hypercholesterolemia and related cardiovascular diseases (Gokce, 2004; Sudar-Milovanovic et al., 2016).


Effect of L-Arginine on Coagulation and Fibrinolysis

There is limited research on how L-arginine affects blood clotting components. However, some studies have shed light on this topic. One study found that exposing human plasma to L-arginine in a lab setting prolonged the time it took for blood to clot and also affected the time it took for blood to form clots in response to certain triggers (Stief et al. [68]). Gryglewski et al. [36] have investigated how L-arginine affects the body's ability to break down blood clots. Researchers found that administering L-arginine to patients with blocked arteries in their legs shortened the time it took for blood clots to dissolve. Additionally, L-arginine reduced the activity of a protein that prevents blood clots from dissolving. Another study Kawabata and Hata [46] found similar results, showing that combining L-arginine with another substance reversed the

substance's effects on blood clotting. Specifically, it shortened the time it took for blood clots to dissolve, reduced the activity of the protein that prevents blood clots from dissolving, and decreased the concentration of a protein involved in blood clotting. Overall, these studies suggest that L-arginine may have a mild effect on blood clotting, potentially by reducing the formation of blood clots and/or increasing the breakdown of existing clots (Radomski et al., 1990; Wu & Morris, 1998).

Asymmetric Dimethyl Arginine (ADMA):

Asymmetric dimethylarginine (ADMA) is an endogenous amino acid that plays a pivotal role in regulating blood flow and cardiovascular health (Bode-Boger et al., 1998; Loscalzo, 2000). Produced through the methylation of arginine residues in proteins by protein arginine methyltransferases (PRMTs), ADMA has been implicated in the pathogenesis of various cardiovascular diseases (Wu & Morris, 1998). Elevated ADMA levels have been consistently linked to hypertension, heart disease, and kidney disease (Gokce, 2004; Cylwik et al., 2005). Research has demonstrated that ADMA inhibits nitric oxide production, a crucial molecule for maintaining healthy blood vessels (Radomski et al., 1990). Furthermore, studies have shown that increased ADMA levels are associated with decreased kidney function and a higher risk of heart attack and stroke (Gornik & Creager, 2004). The effects of ADMA on the cardiovascular system are multifaceted. ADMA increases blood pressure, reduces blood flow to the heart, and impairs blood vessel function (Loscalzo, 2000). Additionally, ADMA enhances the adhesiveness of endothelial cells, contributing to the development of atherosclerosis (Gornik & Creager, 2004). Inhibiting ADMA activity has been proposed as a potential therapeutic strategy for cardiovascular disease management (Sudar-Milovanovic et al., 2016). This can be achieved through the use of drugs that inhibit ADMA production or enhance its degradation (Rodrigues-Krause et al., 2019). Several studies have investigated the potential benefits of ADMA inhibition, including improved blood vessel function, reduced blood pressure, and decreased risk of cardiovascular events (Park et al., 2023).



(Degradation of ADMA)

In addition to its role in cardiovascular disease, ADMA has also been implicated in other conditions, including kidney disease, diabetes, and Alzheimer's disease (Gokce, 2004; Cylwik et al., 2005; Park et al., 2023). Further research is necessary to fully understand the mechanisms underlying ADMA's contribution to these diseases and to develop effective therapeutic strategies for its inhibition (Rodrigues-Krause et al., 2019). ADMA plays a critical role in regulating cardiovascular health, and elevated levels are associated with various cardiovascular diseases (Loscalzo, 2000; Gornik & Creager, 2004). Further research is necessary to fully understand the mechanisms underlying ADMA's contribution to cardiovascular disease and to develop effective therapeutic strategies for its inhibition (Sudar-Milovanovic et al., 2016).

Conclusion:

In conclusion, the available evidence suggests that L-arginine supplementation has beneficial effects on cardiovascular health, particularly in individuals with existing cardiovascular disease or risk factors. L-arginine's ability to improve endothelial function, increase nitric oxide production, and enhance blood flow has been consistently demonstrated in various studies. Additionally, L-arginine may also have anti-inflammatory and anti-oxidative effects,

which can further contribute to its cardiovascular benefits. However, it is essential to note that the effects of L-arginine on cardiovascular health can vary depending on factors such as dosage, duration of supplementation, and individual characteristics. Further research is needed to fully elucidate the mechanisms underlying L-arginine's cardiovascular effects and to determine its potential as a therapeutic agent for cardiovascular disease prevention and treatment. Overall, the evidence suggests that L-arginine supplementation may be a useful adjunctive therapy for individuals with cardiovascular disease or risk factors, and may also be beneficial for healthy individuals seeking to maintain optimal cardiovascular health.

References:

- Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1990). Characterization of the L-arginine: nitric oxide pathway in human platelets. 101, 325-328.
- Bode-Boger, S. M., Boger, R. H., Galland, A., Tsikas, D., & Frolich, J. C. (1998). L-Arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. *Br. J. Clin. Pharmacol.*, 46, 489-497.
- Wu, G., & Morris, S. M., Jr. (1998). Arginine metabolism: nitric oxide and beyond. *Biochem. J.*, 336(1), 1-17.
- Grisham, M. B., Jourdain, D., & Wink, D. A. (1999). Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites: implications in inflammation. *Am. J. Physiol.*, 276(2 Pt 1), G315-321.
- Loscalzo, J. (2000). What We Know and Don't Know About L-Arginine and NO. 101(18), 2126-2129.
- Cylwik, D., Mogielnicki, A., & Buczek, W. (2005). L-arginine and cardiovascular system. 57, 14-22.
- Gornik, H. L., & Creager, M. A. (2004). Arginine and Endothelial and Vascular Health. 134, 2880s-2887s.
- Gokce, N. (2004). L-Arginine and Hypertension. 134, 2807s-2811s.

Dana, E., Arch, G., & Mark, E. (2008). Variation in L-arginine intake follow demographics and lifestyle factors that may impact cardiovascular disease risk. 28(1), 21-24.

Stief, T. W., Weippert, M., Kretschmer, V., & Doss, M. O. (2001). Arginine inhibits hemostasis activation. *Thrombosis Research*, 104(4), 265-274.

Gryglewski, R. J., Grodzinska, L., Kostka-Trabka, E., Korbut, R., Bieroon, K., Goszcz, A., et al. (1996). Treatment with L-arginine is likely to stimulate generation of nitric oxide in patients with peripheral arterial obstructive disease. *Wiener Klinische Wochenschrift*, 108(4), 111-116.

Kawabata, A., & Hata, T. (1996). Attenuation by prolonged nitric oxide synthase inhibition of the enhancement of fibrinolysis caused by environmental stress in the rat. *British Journal of Pharmacology*, 119(2), 346-350.

Sudar-Milovanovic, E., Obradovic, M., Jovanovic, A., Zaric, B., Zafirovic, S., Panic, A., Radak, D., & Isenovic, E. R. (2016). Benefits of L-Arginine on Cardiovascular System. 16, 94-103.

Rodrigues-Krause, J., Krause, M., Gomes da Rocha, Umpierre, D., & Trussardi Fayh, A. P. (2019). Association of l-Arginine Supplementation with Markers of Endothelial Function in Patients with Cardiovascular or Metabolic Disorders: A Systematic Review and Meta-Analysis. 11(1), 15.

Park, H. Y., Kim, S. W., Seo, J., Jung, Y. P., Kim, H., Kim, A. J., Kim, S., & Lim, K. (2023). Dietary Arginine and Citrulline Supplements for Cardiovascular Health and Athletic Performance: A Narrative Review. 15(5), 1268.